The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial

European Radiology

Volumn 26, Issue 8, 2016, Pages 2798-2807

  Jamshidi, Neema ^a   Jonasch, Eric ^b   Zapala, Matthew ^a,c   Korn, Ronald L ^d   Brooks, James D ^e   Ljungberg, Borje ^f   Kuo, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Scottsdale Medical Imaging   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bevacizumab; Imaging biomarker; Imaging surrogate; Radiogenomics; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; PROTEIN KINASE; ANGIOGENESIS INHIBITOR;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE SPECIFIC SURVIVAL; DRUG RESPONSE; FEMALE; GENOMICS; HUMAN; KIDNEY METASTASIS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOGENOMIC RISK SCORE; RENOGRAPHY; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; SURVIVAL TIME; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 84946781085     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-4082-8     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66
2. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18:821–831
3. Kuo MD, Jamshidi N (2014) Behind the numbers: decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. Radiology 270:320–325
4. Banerjee S, Wang DS, Kim HJ et al (2015) A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology. doi:10.1002/hep.27877
5. Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105:5213–5218
6. Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270:1–2
7. Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680
8. Yamamoto S, Han W, Kim Y et al (2015) Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced mr imaging, long noncoding RNA, and metastasis. Radiology. doi:10.1148/radiol.15142698:142698
9. Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576
10. Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology 264:387–396
11. Rizzo S, Petrella F, Buscarino V et al (2015) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. doi:10.1007/s00330-015-3814-0
12. Klein EA, Cooperberg MR, Magi-Galluzzi C et al (2014) A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66:550–560
13. Sestak I, Dowsett M, Zabaglo L et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105:1504–1511
14. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177
15. Jamshidi N, Jonasch E, Zapala M et al (2015) The radiogenomic risk score: construction of a prognostic quantitative, noninvasive image-based molecular assay for renal cell carcinoma. Radiology 277:114–123
16. Jonasch E, Wood CG, Matin SF et al (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27:4076–4081
17. Sun M, Shariat SF, Cheng C et al (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60:644–661
18. Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148
19. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799
20. Motzer RJ, Escudier B, Bukowski R et al (2013) Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 108:2470–2477
21. Zeeberg BR, Feng W, Wang G et al (2003) GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 4:R28
22. Breslow N, Crowley J (1984) A large sample study of the life table and product limit estimates under random censorship. Ann Stat 2:437–453
23. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363
24. Mekhail TM, Abou-Jawde RM, Boumerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841
25. Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35
26. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
27. Lamuraglia M, Raslan S, Elaidi R et al (2015) mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response. Eur Radiol. doi:10.1007/s00330-015-3828-7
28. Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
29. Lindstrom LS, Karlsson E, Wilking UM et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608
30. Arrowsmith J (2011) Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 10:328–329
31. Coffey CS, Levin B, Clark C et al (2012) Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials 9:671–680
32. Ledford H (2013) ‘Master protocol’ aims to revamp cancer trials. Nature 498:146–147